The functional connectome in obsessive-compulsive disorder: resting-state mega-analysis and machine learning classification for the ENIGMA-OCD consortium
- PMID: 37131072
- PMCID: PMC10827654
- DOI: 10.1038/s41380-023-02077-0
The functional connectome in obsessive-compulsive disorder: resting-state mega-analysis and machine learning classification for the ENIGMA-OCD consortium
Erratum in
-
Correction: The functional connectome in obsessive-compulsive disorder: resting-state mega-analysis and machine learning classification for the ENIGMA-OCD consortium.Mol Psychiatry. 2023 Oct;28(10):4320. doi: 10.1038/s41380-023-02211-y. Mol Psychiatry. 2023. PMID: 37582859 Free PMC article. No abstract available.
Abstract
Current knowledge about functional connectivity in obsessive-compulsive disorder (OCD) is based on small-scale studies, limiting the generalizability of results. Moreover, the majority of studies have focused only on predefined regions or functional networks rather than connectivity throughout the entire brain. Here, we investigated differences in resting-state functional connectivity between OCD patients and healthy controls (HC) using mega-analysis of data from 1024 OCD patients and 1028 HC from 28 independent samples of the ENIGMA-OCD consortium. We assessed group differences in whole-brain functional connectivity at both the regional and network level, and investigated whether functional connectivity could serve as biomarker to identify patient status at the individual level using machine learning analysis. The mega-analyses revealed widespread abnormalities in functional connectivity in OCD, with global hypo-connectivity (Cohen's d: -0.27 to -0.13) and few hyper-connections, mainly with the thalamus (Cohen's d: 0.19 to 0.22). Most hypo-connections were located within the sensorimotor network and no fronto-striatal abnormalities were found. Overall, classification performances were poor, with area-under-the-receiver-operating-characteristic curve (AUC) scores ranging between 0.567 and 0.673, with better classification for medicated (AUC = 0.702) than unmedicated (AUC = 0.608) patients versus healthy controls. These findings provide partial support for existing pathophysiological models of OCD and highlight the important role of the sensorimotor network in OCD. However, resting-state connectivity does not so far provide an accurate biomarker for identifying patients at the individual level.
© 2023. The Author(s).
Conflict of interest statement
AA consults and holds equity with Neumora Therapeutics (formerly BlackThorn Therapeutics) and Manifest Technologies. AA also serves on the technology advisory board of Neumora Therapeutics and on the board of directors for Manifest Technologies. AA is a co-inventor on the following patents: AA, Murray JD, Ji JL: Systems and Methods for Neuro-Behavioral Relationships in Dimensional Geometric Embedding (N-BRIDGE), PCT International Application No. PCT/US2119/022110, filed March 13, 2019 and Murray JD, AA, Martin, WJ: Methods and tools for detecting, diagnosing, predicting, prognosticating, or treating a neurobehavioral phenotype in a subject, U.S. Application No.16/149, filed on October 2, 2018, U.S. Application for PCT International Application No.18/054, 009 filed on October 2, 2018. JDF received consultant fees from NOCD, Inc. PM has received in the past 3 years grants, CME-related honoraria, or consulting fees from Angelini, AstraZeneca, Bial Foundation, Biogen, DGS-Portugal, FCT, FLAD, Janssen-Cilag, Gulbenkian Foundation, Lundbeck, Springer Healthcare, Tecnimede and 2CA-Braga. ELN disclosed that she is an unpaid advisory board member of Tourette Association of America and Myriad Genetics. In the last three years, BHS has received royalties from UpToDate, Inc, and Cambridge University Press and a stipend from the American Medical Association for serving as Associate Editor of JAMA-Psychiatry. PMT received unrelated research grant support from Biogen, Inc. All other individually-named authors in- and outside of the ENIGMA-OCD working group reported no biomedical financial interests or potential conflicts of interest.
Figures






References
-
- Torres AR, Prince MJ, Bebbington PE, Bhugra D, Brugha TS, Farrell M, et al. Obsessive-compulsive disorder: prevalence, comorbidity, impact, and help-seeking in the British National Psychiatric Morbidity Survey of 2000. Am J Psychiatry. 2006;163:1978–85. doi: 10.1176/ajp.2006.163.11.1978. - DOI - PubMed
-
- Association AP. Diagnostic and statistical manual of mental disorders: DSM-5. American Psychiatric A, American Psychiatric Association DSMTF, editors. Arlington, VA: American Psychiatric Association; 2013.
-
- Menzies L, Chamberlain SR, Laird AR, Thelen SM, Sahakian BJ, Bullmore ET. Integrating evidence from neuroimaging and neuropsychological studies of obsessive-compulsive disorder: the orbitofronto-striatal model revisited. Neurosci Biobehav Rev. 2008;32:525–49. doi: 10.1016/j.neubiorev.2007.09.005. - DOI - PMC - PubMed
MeSH terms
Substances
Grants and funding
- R01 AG058854/AG/NIA NIH HHS/United States
- P41 EB015922/EB/NIBIB NIH HHS/United States
- R01 MH126213/MH/NIMH NIH HHS/United States
- R21 MH101441/MH/NIMH NIH HHS/United States
- R01 MH121520/MH/NIMH NIH HHS/United States
- R21 MH093889/MH/NIMH NIH HHS/United States
- R01 MH116147/MH/NIMH NIH HHS/United States
- R01 MH111794/MH/NIMH NIH HHS/United States
- R01 MH085900/MH/NIMH NIH HHS/United States
- UL1 TR001863/TR/NCATS NIH HHS/United States
- R01 MH081864/MH/NIMH NIH HHS/United States
- R01 MH104648/MH/NIMH NIH HHS/United States
- U54 EB020403/EB/NIBIB NIH HHS/United States
- R01 MH117601/MH/NIMH NIH HHS/United States
- R01 MH116038/MH/NIMH NIH HHS/United States
- R01 MH126981/MH/NIMH NIH HHS/United States
- R01 NS107513/NS/NINDS NIH HHS/United States
- RF1 MH123163/MH/NIMH NIH HHS/United States
- R33 MH107589/MH/NIMH NIH HHS/United States
- K24 MH121571/MH/NIMH NIH HHS/United States
- IA/CPHE/18/1/503956/WTDBT_/DBT-Wellcome Trust India Alliance/India
- R01 MH121246/MH/NIMH NIH HHS/United States
- WT_/Wellcome Trust/United Kingdom
- K23 MH115206/MH/NIMH NIH HHS/United States
- R01 AG059874/AG/NIA NIH HHS/United States